Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey.

Autor: Di Noia V; Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: vincenzo.dinoia@gavazzeni.it., Riva F; Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Italy., Di Civita M; Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Italy., Cosimati A; Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Italy., Cognetti F; Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Italy.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Nov; Vol. 158, pp. 253-254. Date of Electronic Publication: 2021 Sep 25.
DOI: 10.1016/j.ejca.2021.09.007
Abstrakt: Competing Interests: Conflict of interest statement V.D.N. received speakers' fee by AstraZeneca, MSD, BMS, Istituto Gentili, Boehringer Ingelheim. V.D.N. received grant consultancies by Astrazeneca, MSD, BMS, Boehringer Ingelheim and travels' fee from MSD and Boehringer Ingelheim. V.D.N. received institutional research grants from Roche. F.C. member of advisory board of GSK, Roche, Astra Azeneca, Eli-Lilly. FC received speakers’ fee by GSK, Roche, AstraZeneca, Eli-Lilly, Novartis, Amgen, Pfizer, MSD, BMS, Astellas, Eli-Lilly. All remaining authors have declared no conflicts of interest.
Databáze: MEDLINE
Externí odkaz: